By Fineline Cube 
Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration with SOPHiA Genetics (NASDAQ: SOPH), the global leader in AI‑driven precision medicine. The partnership will integrate the two companies’ core technologies to conduct the first joint validation of SOPHiA’s flagship oncology assays—MSK‑IMPACT and MSK‑ACCESS—on MGI’s advanced T1+ sequencing system.
Partnership Highlights
| Element | Detail |
|---|---|
| Collaborators | Complete Genomics & SOPHiA Genetics |
| Technology Platform | MGI T1+ sequencing platform |
| Target Assays | MSK‑IMPACT & MSK‑ACCESS (developed with Memorial Sloan‑Kettering Cancer Center) |
| Validation Scope | End‑to‑end workflow: sample prep, sequencing, cloud‑based analytics, and report generation |
What This Means for Clinical Oncology Labs
- Streamlined Workflows – The collaboration delivers a single‑pipeline solution that eliminates hand‑offs between laboratories, reducing turnaround times and minimizing error risk.
- AI‑Powered Insight – SOPHiA’s DDM platform applies advanced machine‑learning models to multivariate genomic data, uncovering actionable biomarkers that drive personalized therapy decisions.
- Global Reach – SOPHiA’s platform is already in use by hundreds of institutions worldwide, and the T1+ partnership expands its reach within the U.S. and beyond, enhancing access to high‑quality, next‑generation oncology testing.
About SOPHiA Genetics
Headquartered in Lausanne, Switzerland, SOPHiA Genetics is a pioneer in decentralized collaboration and data‑driven medicine. Its SOPHiA DDM platform transforms complex multimodal data into clinically actionable insights, accelerating both discovery and patient care across oncology, rare diseases, and other therapeutic areas.
Forward‑Looking Statements
This release contains forward‑looking statements. Actual results may differ materially.-Fineline Info & Tech